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Abstract
Background: Cardiac involvement in patients with polymyositis is well-documented and includes
myocarditis, coronary arteritis, pericarditis, valvular dysfunction and arrhythmias.
Case report: There are only few reports of acute myocarditis in patients with polymyositis and,
although it usually follows a chronic, mild course, it may occasionally become life-threatening. We
describe the case of a 36-year-old young woman suffering from polymyositis who presented with
clinical signs and symptoms mimicking an ST Elevation Acute Coronary Syndrome. The atypical
features of the pain, the young age of the woman, the lack of significant cardiovascular risk factors
and the medical history of an autoimmune disease, led us to reconsider our initial diagnosis towards
the presence of focal myocarditis.
Conclusion:  We describe our diagnostic approach and comment on our speculations and
decisions about the treatment of such a life threatening event.
Background
Myocarditis is a clinical entity with a great variety of clin-
ical manifestations, which may range from the totally
asymptomatic state, in the less severe cases, to the severely
ill, haemodynamically-compromised patient, in the case
of fulminant myocarditis.[1-3] Sometimes it can demon-
strate clinical, electrocardiographic and echocardio-
graphic abnormalities simulating an acute myocardial
infarction, from which it may be difficult to be differenti-
ated. [4-6] We present the case of a young woman who
was admitted to our department with symptoms and signs
mimicking an acute myocardial infarction, but who
finally proved to suffer from myocarditis.
Case presentation
A 36-year-old caucasian woman was admitted to our hos-
pital due to a moderate to severe retrosternal pain, com-
mencing 24 hours ago, radiating to the back and being
aggravated with deep breathing. There was no fever, his-
tory of recent viral infection or any other accompanying
symptoms. The woman had been suffering for the last 5
months from a low-grade fever, diffuse myalgias and
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worsening fatigue. She had been fully investigated during
the previous month and was considered to suffer from an
autoimmune disease, yet no definite proof was available.
While waiting for the results of a skin-muscle-vessel and
liver biopsy she was empirically set on corticosteroids and
was discharged from the hospital. A few days later she pre-
sented to us with the previously described pain. From her
medical history she had no significant cardiovascular risk
factor.
On admission she looked ill. She had no dyspnoea and
from her physical examination she had sinus tachycardia,
normal first and second heart sounds, a fourth heart
sound, a mild apical mid-systolic murmur, no pericardial
friction rub and clear lung fields. On chest x-ray the heart
size was normal and there were not any signs of pulmo-
nary congestion. The admission ECG revealed sinus
rhythm, normal QRS axis, a Q-wave at I, aVL and ST-seg-
ment elevation at leads I, aVL, V3-V6 with reciprocal ST-
segment depression at leads III, aVF (figure 1). Cardiac
enzyme levels (troponin, creatin phosphokinase-MB)
were increased. Echocardiography showed a left ventricle
with normal internal dimensions, an apparent regional
hypokinesia of the posterior, the middle and apical seg-
ments of the lateral wall and a mildly compromised glo-
bal systolic function.
The electrocardiographic and echocardiographic findings,
as well as the enzymic activity, were typical of an acute
myocardial infarction. However, the young age of the
patient, the atypical features of chest pain, the lack of sig-
nificant risk factors for coronary artery disease and the
underlying autoimmune disease, led us to reconsider our
diagnosis towards that of acute focal myocarditis. After a
lot of consideration, we decided to initiate high-dose
intravenous corticosteroid treatment, instead of immedi-
ate reperfusion with intravenous thrombolysis (as emer-
gent coronary angiography and possible primary
angioplasty were not available in our setting).
On the following days ST-segment elevations gradually
decreased and negative T-waves appeared at the same
leads, following the pattern of acute myocardial infarction
(figure 2). However, on the third day of hospitalization, a
second echocardiogram revealed the presence of a mural
thrombus attached to the previously recognized hypoki-
netic area (figure 3A). Antithrombotic therapy was initi-
ated (with low molecular weight heparin and
Electrocardiogram on admission Figure 1
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acenocoumarol) and three days later the thrombus gradu-
ally disappeared (figure 3B) without any embolic sequela.
Serial echocardiographic assessment showed that the seg-
mental wall motion abnormality gradually improved and
ten days later the global contractility of the left ventricle
were normal. Similarly, the cardiac enzymes that were ele-
vated on admission returned to normal, following the
pattern of an acute myocardial infarction. The patient
underwent coronary angiography, which revealed normal
coronary arteries and normal systolic function of the left
ventricle.
A few days after her hospital discharge, the previous taken
skin-muscle-vessel biopsy was proved to be diagnostic of
polymyositis. Twelve months later, while being on corti-
costeroids, the patient remains asymptomatic, with a nor-
mal ECG (figure 4), and a normal echocardiogram.
Discussion
Myocarditis is defined as an inflammation of the heart
muscle. [1,7] Although the aetiology of myocarditis in any
given patient often remains unknown, a large variety of
infectious agents such as viruses, bacteria, fungi, protozoa,
and even worms, a variety of autoimmune diseases, drugs,
and toxins have been implicated as causative agents.[1,7-
11]
Viruses are an important cause of myocarditis in North
America and Europe. Infection with Coxsackie B virus spe-
cifically has traditionally percieved as the most frequent
cause of viral myocarditis, causing more than half of the
cases. [12] To establish the diagnosis of myocarditis due
to Coxsackie B virus a distinct increase (usually fourfold)
in virus-neutralizing antibodies has to be demonstrated.
[8-11] In our patient, antibodies titer was not increased
enough (it was detected in the upper normal limit). Con-
sequently, the Coxsackie B4 virus could not be blamed for
Electrocardiogram ten days later Figure 2
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the disease process and the myocarditis should not be
considered of a viral aetiology.
Another cause of myocarditis is the systemic collagen dis-
eases. [7-11] Up to 40% of patients with polymyositis
may have cardiac abnormalities, including AV conduction
defects, tachyarrythmias, pericarditis with effusion, and a
dilated, poorly contracting left ventricle. Rarely, coronary
arteritis has been reported. Accordingly, the evaluation of
a patient with known polymyositis who presents with
chest pain, or even classic angina, and elevated cardiac
enzymes, pose a diagnostic challenge. Besides an acute
coronary syndrome, the differential diagnosis includes
inflammatory myocarditis and coronary arteritis. [7-11]
Our patient was found to suffer from polymyositis with
negative examinations for viral myocarditis or coronary
arteritis, as the coronary angiogram revealed normal coro-
nary arteries. Consequently, in our case, it is quite reason-
able to consider the inflammatory process due to
polymyositis as the likeliest mechanism of myocarditis.
The clinical spectrum of myocarditis is very wide, ranging
from asymptomatic patients to patients with severe left
ventricular dysfunction or even heart failure and cardio-
genic shock, as in cases of and fulminant myocarditis.
Recent studies have reported only few cases of acute myo-
carditis mimicking acute myocardial infarction. [4-6] Dif-
ferential diagnosis often requires cardiac catheterization.
Concerning the treatment, supportive care is the first line
of therapy for patients with myocarditis. In patients with
symptoms of heart failure, therapy should include diuret-
ics, an angiotensin-converting – enzyme inhibitor, and a
beta-blocker once clinical stability has been achieved. In
some patients the intravenous administration of potent
vasodilators, including nitroglycerin or sodium nitroprus-
side, may be required. Digoxin should be used with cau-
tion and only at low doses. In patients with severe
symptoms, supportive care may include the use of intrave-
nous inotropic therapy or implantation of a ventricular
assist device. The presence of either atrial or ventricular
arrhythmias may require appropriate pharmacologic ther-
apy or possibly the implantation of a defibrillator. Bed
rest should strongly be considered during the acute phase,
while patients must be advised to abstain from vigorous
exercise for the following months.
Concerning the usefulness of anticoagulation, most phy-
sicians nowadays suggest that, despite occasional post-
mortem evidence of intracardiac thrombi,
anticoagulation should probably be avoided because of
the risk of a hemorrhagic pericardial effusion. They rec-
ommend it only in patients with apical aneurysm with
thrombus (eg, Chagas disease), atrial fibrillation, prior
embolic events. [7-11] In our patient it was the presence
of the mural thrombus and the direct risk of thromboem-
bolism that forced us to the use of anticoagulants, fortu-
nately with favorable results, rapid resolution of the
thrombus without any embolic event. Our patient
remained on anticoagulants for the next six months.
Two points of controversy about the treatment of myocar-
ditis were until recently immunosuppression therapy and
endomyocardial biopsy. Many clinicians believe that
A. Apical four chamber view Figure 3
A. Apical four chamber view. It depicts a thrombus in the apex (arrows) Abbreviations: LV:left ventricle, RV: right ventri-
cle, LA: left atrium, RA: right atrium, THRO: thrombus. B. The thrombus has disappeared after anticoagulant therapy. Abbrevi-
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immunosuppression may be beneficial in patients with
myocarditis and this hypothesis has been supported by a
large number of uncontrolled clinical studies. However,
the results of more recent randomized, placebo-control-
led trials have failed to demonstrate any beneficial effects
of immunosuppression. [13,14] Taken together, these
studies suggest that immunosuppression should not be
used in the routine treatment of patients with myocardi-
tis. [1,8,9] Such therapy may have an important role in the
treatment of patients with new onset, rapidly deteriorat-
ing, advanced heart failure with suspicion of the following
conditions: giant cell myocarditis, eosinophilic, sarcoid or
systemic autoimmune myocarditis. [1,7-9] Regarding
myocarditis induced by polymyositis, there are no con-
trolled trials to guide treatment decisions. In severe cases,
a pulse regimen of several grams of methylprednisolone is
often prescribed. Many clinicians frequently use a second
agent (methotrexate, azathioprine, cyclosporine, tac-
rolimus) along with corticosteroids from the outset or if
the patient demonstrates a chronic requirement for high
dose corticosteroid therapy. Long term immunosuppres-
sive therapy is frequently required. [11] Novel specific
immunosuppressive agents, including interferon-beta,
aim at interrupting myocyte injury and apoptosis and
seem quite promising according to small clinical studies
performed on selected patients. [10] Thus, refractory cases
may respond to the addition of high intravenous immu-
noglobulin therapy.
Routine endomyocardial biopsy for the confirmation of
myocarditis is considered unnecessary in modern litera-
ture. [1,8-10] There is a low incidence (10%) of biopsy-
proven myocarditis in new onset, unexplained heart fail-
ure and false positive rates are high (50% even in four of
five biopsies). Furthermore, multiple biopsies (about
seven) are needed to increase sensitivity to 90%. However,
Electrocardiogram one year later Figure 4
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endomyocardial biopsy may be considered in patients
with the following conditions: a) rapidly progressive heart
failure symptoms despite conventional therapy or malig-
nant arrhythmias and b) suspected specific causes of myo-
carditis (eg, giant cell myocarditis).[9]
In our patient, treatment with corticosteroids was really
accompanied with an apparent favorable outcome. We
did not perform endomyocardial biopsy because there
was a quick and progressive remission of symptoms and
improvement of myocardial performance that still lasts,
one year after the first appearance.
Conclusion
Consequently, we could say that focal myocarditis mim-
icking acute myocardial infarction, due to polymyositis, is
an unusual clinical setting to our knowledge. Clinicians
should have in mind the rare possibility of myocarditis,
when a patient with an autoimmune background presents
with a clinical manifestation mimicking an acute coronary
syndrome. The differential diagnosis may be difficult and
require coronary angiography, but correct diagnosis is life
– saving for the patient.
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